These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10345969)

  • 1. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.
    Langley PC; Tyring SK; Smith MH
    Am J Manag Care; 1999 Jan; 5(1):69-77. PubMed ID: 10345969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France].
    Lafuma A; Monsonego J; Moyal-Barracco M; Pribil C
    Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):731-6. PubMed ID: 14576602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations.
    Sauder DN; Skinner RB; Fox TL; Owens ML
    Sex Transm Dis; 2003 Feb; 30(2):124-8. PubMed ID: 12567169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts.
    Langley PC
    J Med Econ; 2010 Mar; 13(1):1-7. PubMed ID: 19929627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
    Schöfer H
    Br J Dermatol; 2007 Dec; 157 Suppl 2():52-5. PubMed ID: 18067633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod for anogenital warts in non-immunocompromised adults.
    Grillo-Ardila CF; Angel-Müller E; Salazar-Díaz LC; Gaitán HG; Ruiz-Parra AI; Lethaby A
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010389. PubMed ID: 25362229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
    Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
    Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health economic evaluation of topical treatments for external anogenital warts.
    Agbeci H; Rollot O; Derancourt C; Baglione Q; Benard A; Bertolotti A
    Ann Dermatol Venereol; 2024 Sep; 151(3):103288. PubMed ID: 39002407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies.
    Langley PC; Richwald GA; Smith MH
    Clin Ther; 1999 Dec; 21(12):2143-55. PubMed ID: 10645759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of treating genital warts.
    Strauss MJ; Khanna V; Koenig JD; Downs SM; Goldberg SH; Manyak MJ; Patsner B
    Int J Dermatol; 1996 May; 35(5):340-8. PubMed ID: 8734656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts.
    Bonnez W; Elswick RK; Bailey-Farchione A; Hallahan D; Bell R; Isenberg R; Stoler MH; Reichman RC
    Am J Med; 1994 May; 96(5):420-5. PubMed ID: 8192173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women.
    Garland SM; Waddell R; Mindel A; Denham IM; McCloskey JC
    Int J STD AIDS; 2006 Jul; 17(7):448-52. PubMed ID: 16820073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod: a review of its use in genital warts.
    Perry CM; Lamb HM
    Drugs; 1999 Aug; 58(2):375-90. PubMed ID: 10473026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
    Moresi JM; Herbert CR; Cohen BA
    Pediatr Dermatol; 2001; 18(5):448-50; discussion 452. PubMed ID: 11737696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.
    Tyring SK; Arany I; Stanley MA; Tomai MA; Miller RL; Smith MH; McDermott DJ; Slade HB
    J Infect Dis; 1998 Aug; 178(2):551-5. PubMed ID: 9697742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts.
    Brady S; Wilson JD
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):314-7. PubMed ID: 15096142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of treatment of genital warts with podophyllotoxin.
    Mohanty KC
    Int J STD AIDS; 1994; 5(4):253-6. PubMed ID: 7948154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using imiquimod for genital warts in female patients.
    Cox JT; Petry KU; Rylander E; Roy M
    J Womens Health (Larchmt); 2004 Apr; 13(3):265-71. PubMed ID: 15130255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital warts.
    Buck HW
    Clin Evid; 2006 Jun; (15):2149-61. PubMed ID: 16973081
    [No Abstract]   [Full Text] [Related]  

  • 20. Imiquimod in clinical practice.
    Edwards L
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S14-6. PubMed ID: 9842096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.